CN113260632A - 包含IgA抗体构建体的组合物和方法 - Google Patents

包含IgA抗体构建体的组合物和方法 Download PDF

Info

Publication number
CN113260632A
CN113260632A CN201980087109.4A CN201980087109A CN113260632A CN 113260632 A CN113260632 A CN 113260632A CN 201980087109 A CN201980087109 A CN 201980087109A CN 113260632 A CN113260632 A CN 113260632A
Authority
CN
China
Prior art keywords
antibody construct
heavy chain
amino acid
iga
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980087109.4A
Other languages
English (en)
Chinese (zh)
Inventor
马克·德波尔
珍妮特·亨利卡·威廉明娜·勒森
吉尔特·简·范泰特林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UMC Utrecht Holding BV
TigaTx Inc
Original Assignee
UMC Utrecht Holding BV
TigaTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UMC Utrecht Holding BV, TigaTx Inc filed Critical UMC Utrecht Holding BV
Publication of CN113260632A publication Critical patent/CN113260632A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980087109.4A 2018-10-29 2019-10-29 包含IgA抗体构建体的组合物和方法 Pending CN113260632A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18203183.1 2018-10-29
EP18203183 2018-10-29
US201862752641P 2018-10-30 2018-10-30
US62/752,641 2018-10-30
PCT/US2019/058648 WO2020092427A1 (en) 2018-10-29 2019-10-29 COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS

Publications (1)

Publication Number Publication Date
CN113260632A true CN113260632A (zh) 2021-08-13

Family

ID=70462698

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980087109.4A Pending CN113260632A (zh) 2018-10-29 2019-10-29 包含IgA抗体构建体的组合物和方法

Country Status (9)

Country Link
US (1) US20210332131A1 (https=)
EP (1) EP3873942A4 (https=)
JP (2) JP2022506761A (https=)
KR (1) KR20210096612A (https=)
CN (1) CN113260632A (https=)
AU (1) AU2019369397A1 (https=)
CA (1) CA3118312A1 (https=)
GB (1) GB2596411B (https=)
WO (1) WO2020092427A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114096559A (zh) * 2019-03-27 2022-02-25 蒂嘉特克斯公司 工程化iga抗体及其使用方法
CN116731161A (zh) * 2021-09-18 2023-09-12 南开大学 工程化IgG和IgA嵌合的“四叶草型X抗体”

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3196402A1 (en) * 2020-10-22 2022-04-28 Dale L. Ludwig Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
WO2022125439A2 (en) * 2020-12-07 2022-06-16 The Regents Of The University Of California Innate immune cell silencing by sirp-alpha engager
WO2023154730A2 (en) * 2022-02-09 2023-08-17 Exelixis, Inc. Multispecific binding agents and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120282174A1 (en) * 2009-09-15 2012-11-08 Weissman Irving L Synergistic Anti-CD47 Therapy for Hematologic Cancers
CN105121467A (zh) * 2012-12-03 2015-12-02 诺夫免疫股份有限公司 抗cd47抗体及其使用方法
CN107108748A (zh) * 2014-08-15 2017-08-29 默克专利有限公司 SIRPα免疫球蛋白融合蛋白
CN107459579A (zh) * 2016-06-01 2017-12-12 泰州迈博太科药业有限公司 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用
US20180030142A1 (en) * 2014-08-08 2018-02-01 The Board of Trustees of the Leland Stand Stanford Junior University Sirp alpha-antibody fusion proteins
CN108290948A (zh) * 2015-09-21 2018-07-17 伊拉兹马斯大学医疗中心 抗-cd47抗体及使用方法
WO2018137705A1 (en) * 2017-01-26 2018-08-02 Zai Lab (Shanghai) Co., Ltd. Cd47 antigen binding unit and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226878D0 (en) * 2002-11-18 2002-12-24 Univ Warwick Antibodies
ES2672640T3 (es) * 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
HRP20170374T1 (hr) * 2008-09-26 2017-05-05 Ucb Biopharma Sprl Biološki proizvodi
WO2013087912A1 (en) * 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
US20140213771A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Multi-specific binding proteins
AU2014227638A1 (en) * 2013-03-15 2015-09-17 Merck Patent Gmbh Tetravalent bispecific antibodies
BR112016015140A2 (pt) * 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
HUE073389T2 (hu) * 2016-09-01 2026-01-28 Tigatx Inc CD20 antitestek
AU2018308191B2 (en) * 2017-07-24 2023-12-21 Scenic Immunology B.V. Treating pathological conditions by direct and indirect targeting of SIRPa - CD47 interaction
ES2933256T3 (es) * 2017-08-08 2023-02-03 Hoffmann La Roche Tratamiento con obinutuzumab de un subgrupo de pacientes con LDLBG

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120282174A1 (en) * 2009-09-15 2012-11-08 Weissman Irving L Synergistic Anti-CD47 Therapy for Hematologic Cancers
CN105121467A (zh) * 2012-12-03 2015-12-02 诺夫免疫股份有限公司 抗cd47抗体及其使用方法
US20180030142A1 (en) * 2014-08-08 2018-02-01 The Board of Trustees of the Leland Stand Stanford Junior University Sirp alpha-antibody fusion proteins
CN107108748A (zh) * 2014-08-15 2017-08-29 默克专利有限公司 SIRPα免疫球蛋白融合蛋白
CN108290948A (zh) * 2015-09-21 2018-07-17 伊拉兹马斯大学医疗中心 抗-cd47抗体及使用方法
CN107459579A (zh) * 2016-06-01 2017-12-12 泰州迈博太科药业有限公司 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用
WO2018137705A1 (en) * 2017-01-26 2018-08-02 Zai Lab (Shanghai) Co., Ltd. Cd47 antigen binding unit and uses thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BOROSS, PETER等: "IgA EGFR antibodies mediate tumour killing in vivo", 《EMBO MOLECULAR MEDICINE》, vol. 5, no. 8, 5 August 2013 (2013-08-05), pages 1213 - 1226 *
EMILY C PICCIONE等: "A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells", 《MABS》, vol. 7, no. 5, 26 August 2015 (2015-08-26), pages 950 *
HULS, G等: "Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies", 《CANCER RESEARCH》, vol. 59, no. 22, 15 November 1999 (1999-11-15), pages 5778 - 5784 *
LEUSEN, JEANETTE H. W.: "IgA as therapeutic antibody", 《MOLECULAR IMMUNOLOGY》, vol. 68, no. 1, 13 November 2015 (2015-11-13), pages 35 - 39 *
LOHSE, STEFAN等: "An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo", 《CANCER RESEARCH》, vol. 76, no. 2, 15 January 2016 (2016-01-15), pages 403 - 417 *
LOHSE, STEFAN等: "Characterization of a Mutated IgA2 Antibody of the m(1) Allotype against the Epidermal Growth Factor Receptor for the Recruitment of Monocytes and Macrophages", 《JOURNAL OF BIOLOGICAL CHEMISTRY》, vol. 287, no. 30, 7 July 2012 (2012-07-07), pages 25139 - 25150 *
LOHSE, STEFAN等: "Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity", 《BRITISH JOURNAL OF HAEMATOLOGY》, vol. 181, no. 3, 27 April 2017 (2017-04-27), pages 413 - 417 *
PETER E. VAN BOMMEL等: "CD20-selective inhibition of CD47-SIRPα "don\'t eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab", 《ONCOIMMUNOLOGY》, vol. 7, no. 2, 31 October 2017 (2017-10-31) *
查莉等: "天然免疫检查点CD47-SIRPα在恶性肿瘤中的研究进展", 《肿瘤防治研究》, vol. 45, no. 8, 25 August 2018 (2018-08-25), pages 604 - 608 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114096559A (zh) * 2019-03-27 2022-02-25 蒂嘉特克斯公司 工程化iga抗体及其使用方法
CN114096559B (zh) * 2019-03-27 2026-03-20 蒂嘉特克斯公司 工程化iga抗体及其使用方法
CN116731161A (zh) * 2021-09-18 2023-09-12 南开大学 工程化IgG和IgA嵌合的“四叶草型X抗体”

Also Published As

Publication number Publication date
CA3118312A1 (en) 2020-05-07
EP3873942A4 (en) 2022-12-28
EP3873942A1 (en) 2021-09-08
GB202107478D0 (en) 2021-07-07
JP2024170456A (ja) 2024-12-10
JP2022506761A (ja) 2022-01-17
KR20210096612A (ko) 2021-08-05
US20210332131A1 (en) 2021-10-28
WO2020092427A1 (en) 2020-05-07
GB2596411B (en) 2023-09-20
GB2596411A (en) 2021-12-29
AU2019369397A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
CN112513085B (zh) Psma结合剂及其用途
CN120058941A (zh) 抗cd3抗体及其用途
US20210332131A1 (en) COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS
CN114096559B (zh) 工程化iga抗体及其使用方法
CN107001476A (zh) 用于增强的免疫应答和癌症治疗的组合物和方法
US20240059789A1 (en) Psma binding proteins and uses thereof
KR102885855B1 (ko) 항-pd-1 항체 및 이의 용도
TW201600527A (zh) 結合人類大麻素１（ｃｂ１）受體之抗體
WO2021008523A1 (zh) 抗tigit抗体及其应用
TWI784932B (zh) 結合人類大麻素1(cb1)受體之抗體
JP2023536631A (ja) 多重特異性結合性作用剤およびその使用
KR20240156628A (ko) 항-cd36 항체 및 이의 이용
HK40059443A (en) Compositions and methods comprising iga antibody constructs
TW202246324A (zh) 用於治療癌症的經掩蔽之ｃｔｌａ４及ｐｄ１／ｐｄｌ１抗體之組合
TW202140565A (zh) 抗ｃｄ４７抗體及其用途
TW202517683A (zh) 可活化之ror結合劑及其用途
CN117580867A (zh) Psma结合蛋白及其用途
HK40067884A (en) Engineered iga antibodies and methods of use
HK40085373A (en) Anti-cd47 antibody and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40059443

Country of ref document: HK